مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

305
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

172
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Generation of CD19-Targeted Chimeric Antigen Receptor T Cells

Pages

  7-10

Abstract

 Background: Current advancements in the field of Chimeric antigen receptor (CAR) therapy, particularly U. S. FDA approval of Kymriah and Yescarta, heralds a new era of cancer treatment. This rapid progress in technology has urged more countries and institutions to keep pace with the fast-growing and developing technology of producing CAR T cell-based therapies in the race to develop new cancer-targeting drugs. Hence, for stepping in line with global advances and to pave the way for subsequent preclinical and clinical studies, we have established a development protocol for a cancer-targeting CAR T cell; we have chosen CD19 CAR T cell as a well-defined model to set-up T cell expansion, activation, and viral transduction as the prerequisites for diverse CAR T cell therapies. Methods: T cells from peripheral blood mononuclear cells (PBMCs) were activated and expanded. CD19 CAR lentiviral particles were produced in the Lenti-X™ 293T Cell Line using PolyFect Transfection Reagent. Results: Activation protocol resulted in (65 ± 4%; P = 0. 046) increase in the rate of activated T cells 24 hours after the initiation of the procedure. The expansion methodology resulted in a high purity of the T cell population (96 ± 3%) in the pool of PBMCs within 14 days of the procedure. Finally, 35 ± 6% of T cells were transduced with CD19 lentivirus with MOI of 3. Conclusion: Collectively, the results of this study prove that we have successfully overcome the first hurdle on the road to reach CAR T cell technology which is the prerequisite for developing preclinical and clinical phases of CAR therapy in settings with basic resources.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    Kiani, Jafar, NADERI, MAHMOOD, Torabi Rahvar, Monireh, RANJBAR, AZAM, AGHAYAN, HAMID REZA, Janzamin, Ehsan, & AHMADBEIGI, NASER. (2019). Generation of CD19-Targeted Chimeric Antigen Receptor T Cells. ARCHIVES OF IRANIAN MEDICINE, 22(1), 7-10. SID. https://sid.ir/paper/281759/en

    Vancouver: Copy

    Kiani Jafar, NADERI MAHMOOD, Torabi Rahvar Monireh, RANJBAR AZAM, AGHAYAN HAMID REZA, Janzamin Ehsan, AHMADBEIGI NASER. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells. ARCHIVES OF IRANIAN MEDICINE[Internet]. 2019;22(1):7-10. Available from: https://sid.ir/paper/281759/en

    IEEE: Copy

    Jafar Kiani, MAHMOOD NADERI, Monireh Torabi Rahvar, AZAM RANJBAR, HAMID REZA AGHAYAN, Ehsan Janzamin, and NASER AHMADBEIGI, “Generation of CD19-Targeted Chimeric Antigen Receptor T Cells,” ARCHIVES OF IRANIAN MEDICINE, vol. 22, no. 1, pp. 7–10, 2019, [Online]. Available: https://sid.ir/paper/281759/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button